ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

anlotinib

Also written as “Anlotinib”, “AL3818” and “AK104+anlotinib”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Endometrial Neoplasms · Small Cell Lung Carcinoma · Neoplasms · Sarcoma, led by 8 companies.

Drug pageAnlotinib: every studyMany companies study it; this page follows only the 40 they lead. All 374 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Dec 30, 201340 company-led studies, 7 open or runningNext primary completion: Mar 31, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceuticalits history only311 open or runningphase 3since Dec 30, 2013Mar 29, 2013none ahead
Advenchen Laboratoriesits history only32 open or runningphase 3since Aug 28, 2015Sep 26, 2014Dec 2027phase 3 · NCT03016819
Advenchen Laboratories Nanjingits history only11 open or runningphase 1since Feb 11, 2026Feb 11, 2026Mar 31, 2027phase 1 · NCT07438886
Advenchen Pharmaceuticals, LLC.its history only11 open or runningphase 2since Aug 12, 2026Aug 12, 2026Sep 1, 2030phase 2 · NCT07811297
Akesoits history only10 open or runningphase 2since Nov 23, 2020Nov 23, 2020none ahead
Fosun Pharma11 open or runningphase 2since Apr 25, 2026Apr 25, 2026Jun 2029phase 2 · NCT07562581
Lyvgen Biopharmaits history only10 open or runningphase 2since Mar 2, 2022Mar 2, 2022none ahead
Shanghai Gopherwood Biotechits history only11 open or runningphase 2since Jan 12, 2023Jan 12, 2023none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Fosun Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 25, 2026First study: phase 2 study in Neoplasm MetastasisFirst studyNCT07562581 · 48 planned · China

Ahead

  1. Jun 2029Primary completion: phase 2 study in Neoplasm MetastasisNCT07562581

TargetBeta

“Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor 3 inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
regorafenibruleBayerphase 440

Studies

The one study Fosun Pharma leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07562581Neoplasm Metastasis · China2RecruitingJun 202948

How it is read

Names in the registry

  • “Anlotinib”, 27 entries
  • “AL3818”, 5 entries
  • “AK104+anlotinib”, 3 entries
  • “luvometinib + anlotinib”, 2 entries
  • “Anlotinib and 14C-labeled Anlotinib”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.